Zimmer Biomet (ZBH) Stock Forecast & Price Target

$91.52 +0.18 (+0.19%)

Closing price 07/10/2026 03:59 PM Eastern

Extended Trading

$91.35 -0.17 (-0.18%)

As of 07/10/2026 07:24 PM Eastern

Compare

Zimmer Biomet - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 24 Analyst Ratings

Sell
3

Hold
13

Buy
8

Based on 24 Wall Street analysts who have issued ratings for Zimmer Biomet in the last 12 months, the stock has a consensus rating of "Hold." Out of the 24 analysts, 3 have given a sell rating, 13 have given a hold rating, 7 have given a buy rating, and 1 has given a strong buy rating for ZBH.

Consensus Price Target

$102.33
11.82% Upside

According to the 24 analysts' twelve-month price targets for Zimmer Biomet, the average price target is $102.33. The highest price target for ZBH is $135.00, while the lowest price target for ZBH is $83.00. The average price target represents a forecasted upside of 11.82% from the current price of $91.52.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ZBH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zimmer Biomet and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZBH Analyst Ratings Over Time

Type	Current Forecast 7/13/25 to 7/13/26	1 Month Ago 6/13/25 to 6/13/26	3 Months Ago 4/14/25 to 4/14/26	1 Year Ago 7/13/24 to 7/13/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)
Hold	13 Hold rating(s)	12 Hold rating(s)	12 Hold rating(s)	9 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$102.33	$102.70	$105.95	$110.00
Forecasted Upside	11.82% Upside	16.00% Upside	9.77% Upside	17.17% Upside
Consensus Rating	Hold	Hold	Hold	Hold

ZBH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ZBH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zimmer Biomet Stock vs. The Competition

Type	Zimmer Biomet	Medical Companies	Broader Market
Consensus Rating Score	2.25	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	11.82% Upside	701.52% Upside	13.82% Upside
News Sentiment Rating	Positive News See Recent ZBH News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/8/2026	BMO Capital Markets 3 of 5 stars	Vik Chopra Not Rated	Initiated Coverage	Outperform ➝ Market Perform	$95.00	+8.39%
7/6/2026	Weiss Ratings 5 of 5 stars		Reiterated Rating	Hold (C-)
5/28/2026	Citigroup 4 of 5 stars	Joanne Wuensch 2 of 5 stars	Lower Target	Neutral	$95.00 ➝ $93.00	+12.16%
4/29/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$83.00	+2.76%
4/29/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$92.00	+13.90%
4/29/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Underweight	$100.00 ➝ $94.00	+13.32%
4/29/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$100.00 ➝ $95.00	+18.30%
4/29/2026	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Turkaly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Market Outperform	$120.00 ➝ $105.00	+29.42%
4/29/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$98.00 ➝ $90.00	+11.43%
4/29/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold	$98.00 ➝ $92.00	+13.94%
Buy this stock today (Ad) Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race. Get the name, ticker, and full Hotlist before markets open
4/29/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$110.00 ➝ $105.00	+26.58%
4/13/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Hold	$101.00	+8.44%
3/23/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Zimmerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
2/20/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Buy ➝ Market Perform
2/11/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Sell	$89.00	-4.14%
2/10/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
1/26/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy
1/9/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lee Hambright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Market Perform	$97.00 ➝ $99.00	+5.24%
1/9/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$93.00	-1.14%
1/5/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	In-Line ➝ Outperform	$94.00 ➝ $120.00	+33.25%
11/6/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$111.00 ➝ $101.00	+15.41%
11/5/2025	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$112.00	+28.01%
9/18/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ed Ridley-Day Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$130.00	+29.92%
8/8/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$104.00 ➝ $113.00	+15.02%
8/7/2025	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
5/6/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Cecilia Furlong Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$115.00 ➝ $95.00	+4.11%
10/15/2024	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$145.00 ➝ $135.00	+29.93%
9/10/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Peer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:24 AM ET.

Should I Buy Zimmer Biomet Stock? ZBH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 12, 2026. Please send any questions or comments about these Zimmer Biomet pros and cons to contact@marketbeat.com.

Zimmer Biomet
Bull Case

Here are some ways that investors could benefit from investing in Zimmer Biomet Holdings, Inc.:

The company has demonstrated strong financial performance, with a recent quarterly revenue increase of over 9% year-over-year, indicating robust demand for its products.
Zimmer Biomet Holdings, Inc. has a solid net margin of approximately 9.05%, reflecting effective cost management and profitability.
With a return on equity of 13.24%, the company is effectively utilizing shareholders' equity to generate profits, which is a positive sign for investors.
The current stock price is around $108, which is within a range that has shown potential for growth based on recent performance metrics.
The company has a low payout ratio of about 24.94%, suggesting that it retains a significant portion of its earnings for reinvestment, which could lead to future growth.

Zimmer Biomet
Bear Case

Investors should be bearish about investing in Zimmer Biomet Holdings, Inc. for these reasons:

The company has set its FY 2026 earnings per share guidance at a range that may not meet investor expectations, which could lead to volatility in stock performance.
Despite recent revenue growth, the overall market for medical devices can be highly competitive and subject to regulatory changes, which may impact future profitability.
Zimmer Biomet Holdings, Inc. operates in a sector that can be sensitive to economic downturns, potentially affecting sales and revenue stability.
The dividend yield is relatively low at around 1.1%, which may not attract income-focused investors looking for higher returns from dividends.
Recent fluctuations in stock price could indicate market uncertainty regarding the company's long-term growth prospects, which may deter risk-averse investors.

ZBH Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Zimmer Biomet is $102.33, with a high forecast of $135.00 and a low forecast of $83.00.

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last twelve months. There are currently 3 sell ratings, 13 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ZBH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares.

According to analysts, Zimmer Biomet's stock has a predicted upside of 11.82% based on their 12-month stock forecasts.

Over the previous 90 days, Zimmer Biomet's stock had 1 upgrade by analysts.

Zimmer Biomet has been rated by research analysts at Barclays, BMO Capital Markets, Canaccord Genuity Group, Citigroup, Citizens Jmp, JPMorgan Chase & Co., Robert W. Baird, Stifel Nicolaus, Truist Financial, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Zimmer Biomet less than other "medical" companies. The consensus rating score for Zimmer Biomet is 2.25 while the average consensus rating score for "medical" companies is 2.30. Learn more on how ZBH compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Zimmer Biomet Recommendations

This page (NYSE:ZBH) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zimmer Biomet (ZBH) Stock Forecast & Price Target

Zimmer Biomet - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ZBH Analyst Ratings Over Time

ZBH Analyst Recommendations By Month

ZBH Price Targets by Month

Zimmer Biomet Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Zimmer Biomet Stock? ZBH Pros and Cons Explained

Zimmer Biomet
Bull Case

Zimmer Biomet
Bear Case

ZBH Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Zimmer Biomet Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zimmer Biomet (ZBH) Stock Forecast & Price Target

Zimmer Biomet - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ZBH Analyst Ratings Over Time

ZBH Analyst Recommendations By Month

ZBH Price Targets by Month

Zimmer Biomet Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Zimmer Biomet Stock? ZBH Pros and Cons Explained

Zimmer Biomet Bull Case

Zimmer Biomet Bear Case

ZBH Forecast - Frequently Asked Questions

What is Zimmer Biomet's forecast for 2026?

Should I buy or sell Zimmer Biomet stock right now?

Does Zimmer Biomet's stock price have much upside?

Has Zimmer Biomet been upgraded by Wall Street analysts recently?

What analysts cover Zimmer Biomet?

Do Wall Street analysts like Zimmer Biomet more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Zimmer Biomet Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Zimmer Biomet
Bull Case

Zimmer Biomet
Bear Case